The prediction results for MBNL1-AS1 sensitivity (50% inhibitory concentration, IC50) suggested that the MBNL1-AS1 high expression group was more sensitive to Ipatasertib drugs and common chemotherapy drugs for prostate cancer, such as Gemcitabine and Docetaxel, whereas the MBNL1-AS1 low expression group was sensitive to Wnt signaling pathway inhibitor drugs, such as Paclitaxel_1080, LGK974_1598 (Figure 8A,B). The gene discussed is PTGDR; the disease is Familial prostate cancer.